Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
264.3 CHF | +11.34% | -0.47% | -8.62% |
12:52pm | AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Buy Recommendation | MT |
12:25pm | Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's enterprise value to sales, at 3.34 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.62% | 214B | - | ||
+43.81% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.35% | 351B | C+ | ||
+19.99% | 328B | B- | ||
+8.10% | 292B | C+ | ||
+11.92% | 216B | B- | ||
+1.96% | 167B | C+ | ||
+7.18% | 165B | C+ | ||
+1.39% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RO Stock
- Ratings Roche Holding AG